Yazar "Cetinkaya, Ayhan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Anesthesia Applications in Experimental Neurological Disease Modeling
    (Duzce Univ, Fac Medicine, 2024) Cetinkaya, Ayhan; Celik, Humeyra
    Neuroscience, which covers the molecular mechanisms employed by the brain to cause neurological diseases and how they can be treated, remains current as the subject of high-budget investigations to develop early diagnosis and new treatment modalities with multidisciplinary approaches. For this purpose, creating the appropriate model with the correct modality and anesthesia in neurological in vivo experimental models is the most important phase to obtain accurate results and ensure animal welfare. To manage anesthesia in rodents, knowing the physiological characteristics of anesthetics and their risks will strengthen experimental procedures. Among the injectable anesthetics, ketamine, xylazine, and pentobarbital are the most frequently preferred agents for general anesthesia in short surgical procedures. Isoflurane and sevoflurane are inhaler anesthetics that are administered through a vaporizer because they are liquids. Important advantages of inhaled anesthetics, such as rapid induction and rapid withdrawal, make inhaled anesthetics stand out in neuroscience studies. In this review, the properties of frequently used anesthetic agents in rodents, their usage methods, and which model they are preferred will be discussed. For this purpose, the selection of appropriate anesthetics in animal models such as epilepsy, Alzheimer's disease, ischemia-reperfusion injury, traumatic brain injury, ischemic stroke, experimental autoimmune encephalomyelitis, and ophthalmic surgical procedures and their side effects will be reviewed.
  • [ X ]
    Öğe
    Electrophysiologic and anti-inflammatorial effects of cyclooxygenase inhibition in epileptiform activity
    (Wiley, 2023) Turel, Canan Akunal; Celik, Humeyra; Cetinkaya, Ayhan; Turel, Idris
    The aim of our study is to investigate the electrophysiological and anti-inflammatory effects of diclofenac potassium on epileptiform activity, which is the liquid form of diclofenac, and frequently used clinically for inflammatory process by inhibiting cyclooxygenase enzyme (COX). Wistar rats aged 2-4 months were divided into Epilepsy, Diazepam, Diclofenac potassium, and Diazepam+diclofenac potassium groups. Diazepam and diclofenac potassium were administered intraperitoneally 30 min after the epileptiform activity was created with penicillin injected intracortically under anesthesia. After the electrophysiological recording was taken in the cortex for 125 min, interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were evaluated by the ELISA in the serums. No change was observed between the groups in serum IL-1 beta, IL-6, and TNF-alpha values. It was observed that the co-administration of diclofenac potassium and diazepam at 51-55, 56-60, 61-65, 111-115, and 116-120 min was more effective in reducing spike amplitude than diclofenac potassium alone (p < 0.05). Single-dose diclofenac potassium did not have an anti-inflammatory effect in epileptiform activity but both diazepam and diclofenac potassium reduced the epileptiform activity.
  • [ X ]
    Öğe
    The therapeutic role of Aronia melanocarpa on cyclophosphamide-induced premature ovarian failure
    (Marmara Univ, Fac Pharmacy, 2024) Celik, Huemeyra; Kara, Sinem; Bozat, Bihter Gokce; Uluc, Firdevs; Cetinkaya, Ayhan; Firat, Tulin
    The purpose of the study was to evaluate the effects of Aronia melanocarpa (A. melanocarpa) extract on ovarian cell apoptosis, vascularization, and follicle reserve in the premature ovarian failure (POF) induced by cyclophosphamide (CYC). After creating a premature ovarian failure model with 100 mg/kg CYC, A. melanocarpa was given to Wistar albino female rats by gavage 15 times every other day (200 mg/kg).Vaginal smears were taken to evaluate the estrus cycles before, during and at the end of the experiment. Histological ovarian follicle count was performed by examining the ovaries with Hematoxylin&Eosin staining. Immunohistochemical evaluation of apoptosis markers of caspase-3 (cas-3), caspase-9 (cas-9) and vascular endothelial growth factor (VEGF) was performed. A. melanocarpa reregulated the estrus cycles in a similar way to the controls by reducing cas-3 and cas-9 in ovarian cells and increasing the number of ovarian cells. While CYC disrupted ovarian vascularization, A. melanocarpa contributed to ovarian reserve by increasing VEGF immunopositivity. In chemotherapy-induced POF, A. melanocarpa extract increases ovarian reserve by providing vascularization, decreasing apoptosis and providing cycle control in female rats.